SCHEMBL3012582

SCHEMBL3012582

CCCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccccc4Br)CC3)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
LMNA P02545 2/20 0.49
MAPK1 P28482 2/20 0.49
SMN1; SMN2 Q16637 9/20 0.44
RAB9A P51151 6/20 0.44
NPC1 O15118 4/20 0.44
MAPT P10636 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 1/20 0.42
AR P10275 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001742 0.93 MEN1 (0.51) MEN1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL3017077 0.89 LMNA (0.49) MEN1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL3007132 0.88 SMN1; SMN2 (0.55) MEN1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL3016322 0.87 MEN1 (0.55) MEN1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL3009993 0.87 CTSS (0.40) MEN1KMT2ALMNAMAPK1
SCHEMBL3021202 0.86 MEN1 (0.47) MEN1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL3005312 0.86 KMT2A (0.47) MEN1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL3019047 0.86 MAPT (0.48) MEN1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL3012242 0.85 MAPT (0.54) MEN1KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL3012821 0.85 LMNA (0.45) MEN1KMT2ALMNAMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.